Evidence / Study 02
MCAO treatment window.
A timeline for the source-reported 2 h, 6 h and 24 h treatment-window narrative.
03 / evidence
The band shows temporal narrative, not a fabricated efficacy axis.
preclinicalMiddle cerebral artery occlusion (MCAO)preclinical_in_vivosource_mapped
Research question
Describe the source-reported acute treatment-window narrative in an MCAO model.
Methods
ModelMCAO
SpeciesRat
InterventionAildenafil phosphate
DoseNot specified in current source
Timing2 h, 6 h and 24 h after the source-described event
ComparatorNot specified in the current source summary
- The current source map describes the timepoints and a functional narrative, but not a numerical efficacy series.
Source results
| Endpoint | Timepoint | Source result |
|---|---|---|
| Investigated treatment timepoint | 2 h | 2 h is one of the source-reported treatment timepoints described as having a favorable effect narrative. |
| Investigated treatment timepoint | 6 h | 6 h is one of the source-reported treatment timepoints described as having a favorable effect narrative. |
| Investigated treatment timepoint | 24 h | 24 h is one of the source-reported treatment timepoints described as having a favorable effect narrative. |
| Motor-function context | — | improvement described in the source summary |
FIG. 02Observed events · temporal lineage
The source narrative spans 2, 6 and 24 h—without an efficacy scale.
Interpretation
The figure communicates the source-reported window narrative, not a ranked efficacy curve.
Limitations
- No numerical motor-function scores, comparator values or statistical outputs are mapped in the current source summary.
Continue exploring
Take the question one layer deeper.
01Global cerebral ischemia: edema and AQP4.A source-mapped mouse study summary with direction-of-effect visualization and explicit limitations.02One canvas. Three connected directions.An interactive, source-aware mechanism narrative across vascular response, neurovascular recovery and neuroprotection.03Aildenafil phosphate, presented with precision.A source-mapped product profile for Aildenafil phosphate tablets, separated from the evidence library.04A precise route for scientific questions.A static first medical-information contact path for evidence and safety questions.